Oxford BioMedica (LON:OXB) Stock Passes Below Two Hundred Day Moving Average of $633.33

Oxford BioMedica plc (LON:OXB) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $633.33 and traded as low as $599.56. Oxford BioMedica shares last traded at $601.00, with a volume of 90,917 shares.

OXB has been the topic of several analyst reports. Peel Hunt restated a “buy” rating on shares of Oxford BioMedica in a research note on Monday, November 4th. Liberum Capital restated a “buy” rating on shares of Oxford BioMedica in a research note on Friday, November 15th.

The company’s 50 day moving average price is GBX 560.30 and its 200 day moving average price is GBX 633.33. The company has a market cap of $461.45 million and a price-to-earnings ratio of -51.81. The company has a debt-to-equity ratio of 10.55, a quick ratio of 1.80 and a current ratio of 2.21.

In other news, insider Lorenzo Tallarigo bought 482 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were acquired at an average cost of GBX 554 ($7.24) per share, for a total transaction of £2,670.28 ($3,489.19). Also, insider Martin Diggle bought 17,953 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of GBX 577 ($7.54) per share, for a total transaction of £103,588.81 ($135,357.13). In the last 90 days, insiders have bought 18,905 shares of company stock worth $10,893,339.

Oxford BioMedica Company Profile (LON:OXB)

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Read More: 52-Week High/Low

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.